These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1913664)

  • 1. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.
    Braunschweiger PG; Jones SA; Johnson CS; Furmanski P
    Cancer Res; 1991 Oct; 51(20):5454-60. PubMed ID: 1913664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole.
    Braunschweiger PG; Kumar N; Constantinidis I; Wehrle JP; Glickson JD; Johnson CS; Furmanski P
    Cancer Res; 1990 Aug; 50(15):4709-17. PubMed ID: 2369744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
    Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
    Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors.
    Braunschweiger PG; Johnson CS; Kumar N; Ord V; Furmanski P
    Cancer Res; 1988 Nov; 48(21):6011-6. PubMed ID: 3262418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
    Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
    Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
    Nakamura S; Kashimoto S; Kajikawa F; Nakata K
    Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells.
    Mimnaugh EG; Monti E; Sebers S; Stetler-Stevenson M; Sinha BK
    Oncol Res; 1992; 4(10):401-12. PubMed ID: 1292755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.
    Xin Y; Lyness G; Chen D; Song S; Wientjes MG; Au JL
    J Urol; 2005 Jul; 174(1):322-7. PubMed ID: 15947683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells.
    Chang MJ; Modzelewski RA; Russell DM; Johnson CS
    Cancer Res; 1996 Feb; 56(4):886-91. PubMed ID: 8631029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
    Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
    Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
    Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
    Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
    Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
    Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
    Higashihara J; Berens ME; Collins LA; Homesley HD; Welander CE
    Gynecol Oncol; 1993 Feb; 48(2):171-9. PubMed ID: 8428687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo.
    Wang Z; Benchekroun MN; Sinha BK
    Anticancer Res; 1994; 14(5A):1723-6. PubMed ID: 7847805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.